RU2394581C2 - ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ - Google Patents

ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ Download PDF

Info

Publication number
RU2394581C2
RU2394581C2 RU2007132181/15A RU2007132181A RU2394581C2 RU 2394581 C2 RU2394581 C2 RU 2394581C2 RU 2007132181/15 A RU2007132181/15 A RU 2007132181/15A RU 2007132181 A RU2007132181 A RU 2007132181A RU 2394581 C2 RU2394581 C2 RU 2394581C2
Authority
RU
Russia
Prior art keywords
day
ftd
dose
drug
days
Prior art date
Application number
RU2007132181/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2007132181A (ru
Inventor
Томохиро ЕМУРА (JP)
Томохиро ЕМУРА
Акира МИТА (JP)
Акира МИТА
Original Assignee
Тайхо Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2394581(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Тайхо Фармасьютикал Ко., Лтд. filed Critical Тайхо Фармасьютикал Ко., Лтд.
Publication of RU2007132181A publication Critical patent/RU2007132181A/ru
Application granted granted Critical
Publication of RU2394581C2 publication Critical patent/RU2394581C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2007132181/15A 2005-01-26 2006-01-25 ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ RU2394581C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/042,059 2005-01-26
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005-165156 2005-06-06
JP2005165156 2005-06-06

Publications (2)

Publication Number Publication Date
RU2007132181A RU2007132181A (ru) 2009-03-10
RU2394581C2 true RU2394581C2 (ru) 2010-07-20

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007132181/15A RU2394581C2 (ru) 2005-01-26 2006-01-25 ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ

Country Status (21)

Country Link
EP (1) EP1849470B2 (index.php)
JP (1) JP5576591B2 (index.php)
KR (1) KR101468216B1 (index.php)
AU (1) AU2006209547C1 (index.php)
BE (1) BE2017C028I2 (index.php)
CA (1) CA2594713A1 (index.php)
CY (2) CY2017029I2 (index.php)
DK (1) DK1849470T4 (index.php)
ES (1) ES2630002T5 (index.php)
FI (1) FI1849470T4 (index.php)
FR (1) FR17C1028I2 (index.php)
HU (2) HUE033306T2 (index.php)
LT (2) LT1849470T (index.php)
LU (1) LUC00036I2 (index.php)
NL (1) NL300889I2 (index.php)
PL (1) PL1849470T5 (index.php)
PT (1) PT1849470T (index.php)
RU (1) RU2394581C2 (index.php)
SI (1) SI1849470T2 (index.php)
TW (1) TWI362265B (index.php)
WO (1) WO2006080327A1 (index.php)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340808B2 (en) 2012-03-14 2016-05-17 Nisshin Pharma Inc. Sulfur amino acid-containing composition
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
RU2639473C2 (ru) * 2012-02-15 2017-12-21 Тайхо Фармасьютикал Ко., Лтд. Пероральная фармацевтическая композиция
RU2727598C2 (ru) * 2016-02-05 2020-07-22 Тайхо Фармасьютикал Ко., Лтд. Способ лечения больных раком с тяжелой почечной недостаточностью

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112014028420A2 (pt) * 2012-05-16 2017-09-19 Novartis Ag regime de dosagem para um inibidor de quinase pi-3
US9616081B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
RS60958B1 (sr) * 2013-03-27 2020-11-30 Taiho Pharmaceutical Co Ltd Antitumorski agens koji uključuje irinotekan hidrohlorid hidrat
NZ714014A (en) * 2013-05-17 2017-06-30 Taiho Pharmaceutical Co Ltd Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
LT3042669T (lt) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Priešvėžinis agentas ir stipriklis su priešvėžiniu poveikiu
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763529B1 (en) * 1995-03-29 2003-07-23 Taiho Pharmaceutical Company Limited Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
JP3088758B2 (ja) * 1996-09-24 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体を含有する癌転移抑制剤
JP5576591B2 (ja) 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Tomohiro Emura et al. International Journal of Molecular Medicine. Vol.13, №2, 2004, pp.249-255. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
US9371380B2 (en) 2011-08-16 2016-06-21 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer
RU2639473C2 (ru) * 2012-02-15 2017-12-21 Тайхо Фармасьютикал Ко., Лтд. Пероральная фармацевтическая композиция
US9340808B2 (en) 2012-03-14 2016-05-17 Nisshin Pharma Inc. Sulfur amino acid-containing composition
RU2727598C2 (ru) * 2016-02-05 2020-07-22 Тайхо Фармасьютикал Ко., Лтд. Способ лечения больных раком с тяжелой почечной недостаточностью
US10960004B2 (en) 2016-02-05 2021-03-30 Taiho Pharmaceutical Co., Ltd. Method for treating cancer patients with severe renal impairment

Also Published As

Publication number Publication date
FR17C1028I1 (index.php) 2017-09-29
PL1849470T5 (pl) 2024-06-10
EP1849470A1 (en) 2007-10-31
ES2630002T3 (es) 2017-08-17
EP1849470B1 (en) 2017-06-21
KR101468216B1 (ko) 2014-12-03
EP1849470B2 (en) 2024-03-20
CY2017029I1 (el) 2018-02-14
CY2017029I2 (el) 2018-02-14
SI1849470T2 (sl) 2024-05-31
NL300889I2 (nl) 2018-01-16
PT1849470T (pt) 2017-09-22
PL1849470T3 (pl) 2017-11-30
SI1849470T1 (sl) 2017-10-30
AU2006209547B2 (en) 2011-05-26
TW200637562A (en) 2006-11-01
NL300889I1 (nl) 2017-08-14
LUC00036I2 (index.php) 2017-12-01
KR20070104559A (ko) 2007-10-26
CY1119393T1 (el) 2018-02-14
JPWO2006080327A1 (ja) 2008-06-19
HUS1700032I1 (hu) 2017-09-28
LTC1849470I2 (lt) 2019-10-25
ES2630002T5 (es) 2024-09-19
WO2006080327A1 (ja) 2006-08-03
DK1849470T3 (en) 2017-08-14
BE2017C028I2 (index.php) 2025-09-10
LUC00036I1 (index.php) 2017-10-02
LTPA2017024I1 (lt) 2017-08-10
HUE033306T2 (hu) 2017-11-28
JP5576591B2 (ja) 2014-08-20
EP1849470A4 (en) 2010-12-08
FI1849470T4 (fi) 2024-03-22
RU2007132181A (ru) 2009-03-10
AU2006209547A1 (en) 2006-08-03
AU2006209547C1 (en) 2022-04-07
LT1849470T (lt) 2017-07-25
FR17C1028I2 (fr) 2018-11-02
CA2594713A1 (en) 2006-08-03
TWI362265B (en) 2012-04-21
DK1849470T4 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
RU2394581C2 (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US20120157472A1 (en) Method for treating colorectal cancer
HUP0103640A2 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
US12544370B2 (en) Methods for cancer therapy
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
SG187828A1 (en) Novel combination therapy for the treatment of cancer
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
JP2016014051A (ja) ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
KR100740079B1 (ko) 당뇨병성 신경 장해용 의약 조성물
HK40059774A (en) Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer
TW200846013A (en) Cytidine derivative-containing antitumor agent for continuous intravenous administration
CN109152761A (zh) 使用吲唑基苯甲酰胺衍生物治疗癌症的组合疗法
JP2003300888A (ja) 抗腫瘍効果増強剤
EP3246029A1 (en) Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer